Objective To observe the effect of rosuvastatin and atorvastatin therapy on pregnancy-associated plasma protein-A(PAPP-A) in the patients with coronary heart disease(CHD). Meth-otis 117 patients with CHD verified by invasive coronary angiography were selected. Of them,46 had acute coronary syndrome(ACS,including non-ST-elevation myocardial infarction and unstable angina) and 71 had stable angina, They were randomly assigned to rosuvastatin(60 patients) and atorvastatin(57 patients) groups. PAPP-A, hs-CRP and lipids were measured before and after 1 and 6 months therapy. Results PAPP-A and hs-CRP were significantly increased in 46 patients with ACS compared with 71 patients with stable CHD (P<0.05). After 1 and 6 months therapy with rosuvastatin the level of PAPP-A was significantly decreased compared with baseline. Al-though the level of PAPP-A in atorvastatin group did not show difference at 1 month,it was sig-nificantly decreased at 6 months. Although the level of hs-CRP in both rosuvastatin and atorvasta-tin groups did not show difference at 1 month compared with baseline, it was significantly de-creased at 6 months (P < 0.05). There was no significant correlation between PAPP-A and hs-CRP. Conclusion Levels of PAPP-A and hs-CRP were significantly increased in patients with ACS compared with stable CAD, whereas they were significantly decreased in patients treated with rosuvastatin and atorvastatin.%目的 观察瑞苏伐他汀和阿托伐他汀治疗对冠心病患者妊娠相关血清蛋白A(PAPP-A)和血清高敏C反应蛋白(hs-CRP)的表达变化.方法 选择临床确诊的冠心痛患者117例,其中非ST段括高心肌梗死和不稳定性心绞痛患者46例统称为急性冠状动脉综合征(ACS),稳定性心绞痛71例,随机分为瑞苏伐他汀组(60例)和阿托伐他汀组(57例).分别测量治疗前以及治疗30天和6个月血清中PAPP-A、hs-CRP和血脂的变化情况.结果 与稳定性心绞痛患者比较,ACS患者PAPP-A和hs-CRP明显升高(P<0.05).瑞苏伐他汀组患者PAPP-A水平在治疗30天及6个月较治疗前明显下降,差异有统计学意义(P<0.05);阿托伐他汀组患者在治疗30天PAPP-A水平没有明显变化,6个月时则明显下降(P<0.05);两组患者hs-CRP水平在治疗30天较治疗前没有明显变化,但治疗6个月时则明显下降(P<0.05).PAPP-A与hs-CRP的表达没有相关性.结论 PAPP-A和hs-CRP水平在ACS患者中明显升高,瑞苏伐他汀和阿托伐他汀均能够降低冠心病患者血清中PAPP-A和hs-CRP水平.
展开▼
